Florida
CNS medication trials in Florida
142 CNS medication studies are recruiting participants at sites in 67 cities across Florida as of November 17, 2026, according to ClinicalTrials.gov.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Browse Florida by city
Cities with the most studies recruiting right now.
Miami
55 studies recruiting.
Tampa
54 studies recruiting.
Orlando
48 studies recruiting.
Hollywood
31 studies recruiting.
Jacksonville
30 studies recruiting.
Maitland
26 studies recruiting.
West Palm Beach
25 studies recruiting.
Every Florida city with a recruiting study
By research area: Depression (38), Schizophrenia (25), Parkinson's Disease (24), Migraine (17), Epilepsy (15), Multiple Sclerosis (12), Bipolar Disorder (6), ADHD (5).
Miami (55), Tampa (54), Orlando (48), Hollywood (31), Jacksonville (30), Maitland (26), West Palm Beach (25), Miami Lakes (18), Naples (16), Hialeah (15), Boca Raton (12), Gainesville (12), Boynton Beach (7), Fort Myers (7), Gulf Breeze (7), Miami Gardens (7), Orange City (7), Altamonte Springs (6), Doral (6), Hallandale (6), Winter Park (6), Homestead (5), Weston (5), Atlantis (4), Aventura (4), Brandon (4), Palm Bay (4), St. Petersburg (4), Tamarac (4), Bonita Springs (3), Bradenton (3), Coral Gables (3), DeLand (3), Lauderhill (3), Miami Beach (3), The Villages (3), Clermont (2), Daytona Beach (2), Lakeland (2), Largo (2), Miami Springs (2), Ocoee (2), Ormond Beach (2), Pompano Beach (2), Port Charlotte (2), Riverview (2), Saint Augustine (2), Sarasota (2), Cape Coral (1), Clearwater (1), Cooper City (1), Davie (1), Deerfield Beach (1), Fort Lauderdale (1), Kissimmee (1), Lady Lake (1), Margate (1), North Miami (1), Ocala (1), Pensacola (1), Pinellas Park (1), Port Orange (1), Port Saint Lucie (1), Spring Hill (1), Tallahassee (1), Vero Beach (1), Virginia Gardens (1).
The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.
Depression: recently updated in Florida
Basic details from each study's public record (the 12 most recently updated of 142). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder
- Phase 2
- Ages 18 to 65
- All sexes
- Sponsor
- Alkermes, Inc.
- Recruiting in
- Jacksonville
- Registry record
- NCT07901179 · updated
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Recruiting in
- Jacksonville · Miami · Orlando · and 2 more U.S. locations
- Registry record
- NCT07226661 · updated
Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Florida on ClinicalTrials.gov.
Parkinson's disease: recently updated in Florida
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Fort Lauderdale · Miami
- Registry record
- NCT06623422 · updated
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Altamonte Springs · Orlando · West Palm Beach
- Registry record
- NCT06841354 · updated
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Fort Myers · Gainesville · Miami Beach · and 3 more U.S. locations
- Registry record
- NCT06952504 · updated
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Altamonte Springs · Fort Myers · Hialeah · and 2 more U.S. locations
- Registry record
- NCT06966700 · updated
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Fort Myers · Miami Beach · Tampa · and 1 more U.S. location
- Registry record
- NCT07216703 · updated
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- AstraZeneca
- Recruiting in
- Fort Myers · Miami Beach · Orlando · and 3 more U.S. locations
- Registry record
- NCT06989112 · updated
Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease
- Phase 2
- Ages 40 to 85
- All sexes
- Sponsor
- Hoffmann-La Roche
- Recruiting in
- Boca Raton
- Registry record
- NCT07781644 · updated
Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Florida on ClinicalTrials.gov.
Epilepsy: recently updated in Florida
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
- Phase 4
- Ages 18 and older
- All sexes
- Sponsor
- VA Office of Research and Development
- Recruiting in
- Miami
- Registry record
- NCT04419272 · updated
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Rapport Therapeutics Inc.
- Recruiting in
- Gulf Breeze
- Registry record
- NCT07563881 · updated
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Rapport Therapeutics Inc.
- Recruiting in
- Maitland · Miami
- Registry record
- NCT07594119 · updated
Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Florida on ClinicalTrials.gov.
Ask about studies in Florida
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.
CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections